Clinical Use of Natriuretic Peptides

Clinical Use of Natriuretic Peptides

Either B-type natriuretic peptide (BNP) or NT-proBNP may be used as a diagnostic, screening, prognostic and therapeutic tool for CHF. The Food and Drug Administration (FDA) cleared the cut-off point for BNP at 100 pg/mL, and that of NT-proBNP at 125 pg/mL for patients <75 years and 450 pg/mL for...

Full description

Bibliographic Details
Main Authors: Clementine YF Yap MT(ASCP), DLM(ASCP), Soon Kieng Phua BSc, Tar Choon Aw FRCP (Edin), FRCPA
Format: Article
Language:English
Published: SAGE Publishing 2011-12-01
Series:Proceedings of Singapore Healthcare
Online Access:https://doi.org/10.1177/201010581102000410
id doaj-8b9e47ccb5754dd1800d6604345bf24b
record_format Article
spelling doaj-8b9e47ccb5754dd1800d6604345bf24b2020-11-25T03:18:22ZengSAGE PublishingProceedings of Singapore Healthcare2010-10582059-23292011-12-012010.1177/201010581102000410Clinical Use of Natriuretic PeptidesClementine YF Yap MT(ASCP), DLM(ASCP)Soon Kieng Phua BScTar Choon Aw FRCP (Edin), FRCPAEither B-type natriuretic peptide (BNP) or NT-proBNP may be used as a diagnostic, screening, prognostic and therapeutic tool for CHF. The Food and Drug Administration (FDA) cleared the cut-off point for BNP at 100 pg/mL, and that of NT-proBNP at 125 pg/mL for patients <75 years and 450 pg/mL for those >75. A steadily rising titre even below the cut-off value should be raised as a concern as heart failure is progressive if left untreated and may result in cardiac death. Both biomarkers are also featured in lab investigations for patients with acute coronary syndrome (ACS).https://doi.org/10.1177/201010581102000410
collection DOAJ
language English
format Article
sources DOAJ
author Clementine YF Yap MT(ASCP), DLM(ASCP)
Soon Kieng Phua BSc
Tar Choon Aw FRCP (Edin), FRCPA
spellingShingle Clementine YF Yap MT(ASCP), DLM(ASCP)
Soon Kieng Phua BSc
Tar Choon Aw FRCP (Edin), FRCPA
Clinical Use of Natriuretic Peptides
Proceedings of Singapore Healthcare
author_facet Clementine YF Yap MT(ASCP), DLM(ASCP)
Soon Kieng Phua BSc
Tar Choon Aw FRCP (Edin), FRCPA
author_sort Clementine YF Yap MT(ASCP), DLM(ASCP)
title Clinical Use of Natriuretic Peptides
title_short Clinical Use of Natriuretic Peptides
title_full Clinical Use of Natriuretic Peptides
title_fullStr Clinical Use of Natriuretic Peptides
title_full_unstemmed Clinical Use of Natriuretic Peptides
title_sort clinical use of natriuretic peptides
publisher SAGE Publishing
series Proceedings of Singapore Healthcare
issn 2010-1058
2059-2329
publishDate 2011-12-01
description Either B-type natriuretic peptide (BNP) or NT-proBNP may be used as a diagnostic, screening, prognostic and therapeutic tool for CHF. The Food and Drug Administration (FDA) cleared the cut-off point for BNP at 100 pg/mL, and that of NT-proBNP at 125 pg/mL for patients <75 years and 450 pg/mL for those >75. A steadily rising titre even below the cut-off value should be raised as a concern as heart failure is progressive if left untreated and may result in cardiac death. Both biomarkers are also featured in lab investigations for patients with acute coronary syndrome (ACS).
url https://doi.org/10.1177/201010581102000410
work_keys_str_mv AT clementineyfyapmtascpdlmascp clinicaluseofnatriureticpeptides
AT soonkiengphuabsc clinicaluseofnatriureticpeptides
AT tarchoonawfrcpedinfrcpa clinicaluseofnatriureticpeptides
_version_ 1724627113515941888

Similar Items